+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Precision Medicine Partnering 2014-2019: Deal Trends, Players and Financials

  • ID: 2300222
  • Report
  • Region: Global
  • 1000 Pages
  • CurrentPartnering
1 of 4

FEATURED COMPANIES

  • 1CellBiO
  • 4D Pharma
  • AC Immune
  • Admera Health
  • AFFiRiS
  • Akers Biosciences
  • MORE
The Global Precision Medicine Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the Precision medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Precision Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Precision Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Precision Medicine partnering deals.

The report presents financial deal term values for Precision Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Precision Medicine partnering field; both the leading deal values and most active Precision Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 900 online deal records of actual Precision Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Precision Medicine dealmaking.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Precision Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Precision Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Precision Medicine dealmaking with a brief summary followed by a comprehensive listing of Precision Medicine deals announced by that company, as well as contract documents, where available.
  • Chapter 5 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014. The chapter is organized by specific Precision Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Precision Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Precision Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Precision Medicine technologies and products.

Key benefits
  • In-depth understanding of Precision Medicine deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Precision Medicine agreements with numerous real life case studies
  • Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies
  • Identify most active Precision Medicine dealmakers since 2014
  • Insight into terms included in a Precision Medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report Scope
Global Precision Medicine Partnering 2014-2019: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Precision Medicine trends and structure of deals entered into by leading companies worldwide.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 1CellBiO
  • 4D Pharma
  • AC Immune
  • Admera Health
  • AFFiRiS
  • Akers Biosciences
  • MORE
1. Introduction

2. Trends in Precision Medicine dealmaking
2.1. Introduction
2.2. Precision Medicine partnering over the years
2.3. Most active Precision Medicine dealmakers
2.4. Precision Medicine partnering by deal type
2.5. Precision Medicine partnering by therapy area
2.6. Deal terms for Precision Medicine partnering
2.6.1 Precision Medicine partnering headline values
2.6.2 Precision Medicine deal upfront payments
2.6.3 Precision Medicine deal milestone payments
2.6.4 Precision Medicine royalty rates

3. Leading Precision Medicine deals
3.1. Introduction
3.2. Top Precision Medicine deals by value

4. Most active Precision Medicine dealmakers
4.1. Introduction
4.2. Most active Precision Medicine dealmakers
4.3. Most active Precision Medicine partnering company profiles

5. Precision Medicine contracts dealmaking directory
5.1. Introduction
5.2. Precision Medicine contracts dealmaking directory

6. Precision Medicine dealmaking by technology type

7. Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Precision Medicine deals by company A-Z
Appendix 2 – Precision Medicine deals by stage of development
Appendix 3 – Precision Medicine deals by deal type
Appendix 4 – Precision Medicine deals by therapy area
Appendix 5 – Deal type definitions

Table of Figures
Figure 1: Precision Medicine partnering since 2014
Figure 2: Active Precision Medicine dealmaking activity since 2014
Figure 3: Precision Medicine partnering by deal type since 2014
Figure 4: Precision Medicine partnering by disease type since 2014
Figure 5: Precision Medicine deals with a headline value
Figure 6: Precision Medicine deals with an upfront value
Figure 7: Precision Medicine deals with a milestone value
Figure 8: Precision Medicine deals with a royalty rate value
Figure 9: Top Precision Medicine deals by value since 2014
Figure 10: Most active Precision Medicine dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 1CellBiO
  • 2bPrecise
  • 2X Oncology
  • 3D Systems
  • 4D Pharma
  • 20/20 GeneSystems
  • 23andMe
  • 48Hour Discovery
  • A*STAR Agency for Science
  • Technology and Research
  • A*STAR Bioinformatics Institute
  • A*STAR Bioprocessing Technology Institute
  • A*STAR Genome Institute of Singapore
  • Abbott Laboratories
  • Abbvie
  • Abcam
  • Abcodia
  • Abramson Cancer Center
  • Academic Medical Center
  • Accelerate Diagnostics
  • AccuGenomics
  • Accu Reference Medical Laboratory
  • AC Immune
  • Acumen Pharmaceuticals
  • Adaptive Biotechnologies
  • Adarza BioSystems
  • Admera Health
  • Aduro BioTech
  • Advanced Cell Diagnostics
  • Advanced Nuclear Medicine Ingredients
  • Advaxis
  • Aelan Cell Technologies
  • Aerocrine
  • Affigen
  • AFFiRiS
  • Affymetrix
  • Age Labs
  • Agendia
  • Agilent Technologies
  • Agios Pharmaceuticals
  • Air Force Research Laboratory
  • AIT Laboratories
  • Akers Biosciences
  • AKESOgen
  • Akili Interactive Labs
  • Albert Einstein College of Medicine
  • Alcyone Lifesciences
  • Alexion Pharmaceuticals
  • Alion Pharmaceuticals
Sample list of companies, more included in the report
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2300222
Adroll
adroll